Previous Article | Next Article ![]()
Molecular and Cellular Biology, February 2003, p. 1044-1053, Vol. 23, No. 3
0270-7306/03/$08.00+0 DOI: 10.1128/MCB.23.3.1044-1053.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Center for Cancer Research and Department of Biology,1 Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139,4 Swiss Institute for Experimental Cancer Research (ISREC), 1066 Epalinges, Switzerland,2 Tufts University School of Veterinary Medicine, Boston, Massachusetts 021113
Received 31 July 2002/ Returned for modification 28 August 2002/ Accepted 23 October 2002
|
|
|---|
|
|
|---|
Studies involving the targeted disruption of Rb in mice have provided significant insight into the function of pRB in normal development and tumor suppression. Mice heterozygous for an Rb mutation develop pituitary and thyroid tumors, which exhibit loss of the remaining wild-type Rb allele (21, 47). Homozygosity for an Rb mutation causes embryonic lethality near embryonic day 14.5 (E14.5) (9, 22, 26). Rb-null embryos are pale and exhibit defects in fetal liver erythropoiesis. Absence of pRB function also causes dramatic defects in the lens, central nervous system (CNS), and peripheral nervous systems (PNS). In these tissues, both inappropriate S-phase entry and high levels of apoptosis are evident (9, 22, 26, 27, 34).
Extensive analyses of the molecular pathways contributing to these phenotypes have been carried out using compound mutant analysis. pRB binds to members of the E2F family of transcription factors to regulate G1-to-S-phase progression (reviewed in reference 10). Compound mutant analysis involving deletion of both Rb and either E2f1 or E2f3 supports a critical role of these transcription factors in Rb function (44, 54). Mutation of both Rb and E2f1 or E2f3 led to reduced levels of the inappropriate S-phase entry and apoptosis in the CNS and lens. The erythropoietic defect was also partially rescued in these compound mutants, extending embryo survival until nearly E17.5. Compound mutant analysis has also implicated the p53 tumor suppressor in apoptosis in the Rb-deficient CNS and lens but not PNS (33, 34). Loss of p53 specifically inhibited apoptosis in the setting of Rb deficiency; inappropriate S-phase and embryonic lethality were not affected. The specific signals that mediate p53 activation in the Rb-/- embryos have not been determined, although it is known that deregulated E2f activity can cause p53 activation in other systems. In cell culture, E2f1 overexpression leads to proliferation and apoptosis that is partially p53 dependent (24, 40, 49). One possible mediator of p53 activation downstream of E2f members is the E2f target ARF, which regulates p53 by inhibiting MDM2 (39) and is induced in mouse embryonic fibroblasts upon E2f1 overexpression (5). However, loss of Arf does not significantly inhibit the CNS or lens apoptosis in Rb mutant embryos (45).
The analysis of chimeric animals composed of both wild-type and Rb-null cells has demonstrated that both the development of erythroid cells and the death of Rb-/- neurons can be rescued (30, 32, 48). With respect to inhibition of apoptosis in the CNS, it is possible that neighboring cells provide survival signals in the form of a secreted factor or perhaps involving cell-cell contacts that allow nearby Rb-deficient cells to survive (30). An alternative possibility is that the survival of CNS neurons is due to the absence of a proapoptotic factor normally present in germ line Rb-/- embryos. Specifically, the normal development of the hematopoietic system in these chimeras may relieve hypoxic stress on the embryo, thus eliminating a critical signal for apoptosis.
The cause of the defect in erythropoiesis in Rb-/- embryos is not known, although it has been proposed that the Rb-deficient fetal liver may not provide an environment supportive of erythrocyte development. Rb mutant fetal livers are hypocellular, have high levels of apoptosis, and produce a deficit of mature, enucleated erythrocytes. However, in Rb+/+:Rb-/- chimeras mature enucleated red blood cells derived from Rb-deficient cells are present (32, 48). Also, fetal livers from Rb-null embryos can reconstitute a lethally irradiated host (20), again suggesting that the environment in which the erythrocytes develop is a critical factor. Given that Rb-/- neurons in chimeras are not prone to apoptosis, we hypothesized that hypoxia downstream of defective erythropoiesis may contribute to p53-dependent apoptosis in the Rb-null CNS.
Upregulation of p53 protein in neurons has been demonstrated upon ischemic injury in vivo (28, 50) and upon hypoxia treatment of neurons cultured in vitro (3, 53). Also, neurons cultured from p53-deficient animals showed resistance to hypoxia-mediated cell death (18), supporting the idea that hypoxia can lead to p53-dependent apoptosis in neurons. It is also possible that hypoxia could contribute to p53-dependent apoptosis in the Rb-/- lens or p53-independent apoptosis in the Rb-/- PNS. In the Rb-/- PNS, the mechanism of apoptosis appears mechanistically distinct from that in the CNS. Apoptosis in this tissue is not affected on a p53-null background (33), and loss of E2f1 or E2f3 only partially reduces the PNS apoptosis in the absence of Rb function (44, 54).
To determine if hypoxia due to the erythropoietic defect was required for apoptosis in the Rb-null embryos, we used a conditional gene-targeting approach to remove Rb from the CNS, PNS, and lens while maintaining normal erythropoiesis. This was carried out using the Cre-loxP system in which Cre expression was driven by regulatory elements from the rat nestin gene (4, 11, 43). In this system, Cre is expressed efficiently in nervous system progenitor cells as well as in other tissues, leading to deletion of Rb in the CNS, PNS, and lens. As such, we were able to examine the fate of Rb-/- cells in these tissues in the presence of an intact hematopoietic system.
|
|
|---|
Northern blotting. Whole-brain tissue was quickly dissected from E13.5 embryos and frozen on dry ice. Tissue was homogenized in Trizol reagent (Invitrogen), and total RNA was isolated following the manufacturer's instructions. Northern blotting with 10 µg of total RNA was performed using standard methods. Vascular endothelial growth factor (VEGF) and lactate dehydrogenase A (LDH-A) cDNAs were used as probes. VEGF cDNA was a gift of Volker Haase and LDH-A cDNA was obtained through reverse transcription-PCR. Probe labeling was performed using the Prime-It II random primer labeling kit (Stratagene) and hybridization was performed using ExpressHyb solution (Clontech).
Southern blotting. Genomic DNA was isolated from E13.5 whole brains following digestion of tissue with proteinase K and extraction with phenol-chloroform. Genomic DNA was digested with PstI and Acc65I, run on a 0.8% agarose gel, transferred to a nylon membrane (Hybond N+; Amersham), and hybridized with a 32P-labeled internal probe as described previously (22).
Western blotting. Whole embryo brain, dorsal root ganglia (DRG), and ocular lens were dissected from E13.5 embryos, and tissue was frozen on dry ice. For DRG microdissection, the E13.5 spinal cord was separated out, and ganglia subsequently were removed from the spinal cord and pooled. Skeletal muscle was dissected from E18.5 embryos. Tissue was lysed in a solution containing 100 mM NaCl, 100 mM Tris (pH 8), 1% NP-40, and Complete protease inhibitor cocktail (Roche). Protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane (Immobilon). Blots were first probed with an antibody to pRB (1/1,000; Pharmingen). Blots were then stripped and reprobed with an antibody to actin (1/1,000; Santa Cruz). Horseradish peroxidase-conjugated secondary antibodies (Jackson Immunochemicals) were used at a 1/5,000 dilution. Enhanced chemiluminescence (ECL+; Amersham) was used for signal detection before exposing blots to film.
Apoptosis and BrdU staining in embryos. For bromodeoxyuridine (BrdU) analysis, pregnant females received intraperitoneal injections of BrdU (Sigma) at 30 µg/g of body weight 1 h before animal sacrifice and embryo dissection. Staining for BrdU was performed as described previously (45). For analysis of apoptosis, terminal deoxynucleotidyltransferase-mediated dUTP-end labeling (TUNEL) was used (14). Paraffin sections were rehydrated, treated with proteinase K, and incubated in TUNEL mixture including biotin-labeled dUTP (Roche) and recombinant terminal deoxynucleotidyltransferase (Invitrogen). Detection of incorporation of biotin-labeled dUTP was done using the ABC kit (Vector Labs) and detection with DAB (Vector Labs).
|
|
|---|
![]() View larger version (58K): [in a new window] |
FIG. 1. Expression of hypoxia-inducible genes in Rb-/- CNS. Northern blotting showing expression levels of the hypoxia-inducible genes VEGF and LDH-A in Rb+/-, Rb-/-, and conditional Rb mutant (CRE) E13.5 whole-brain tissue. ARPP P0 was used as a loading control.
|
![]() View larger version (52K): [in a new window] |
FIG. 2. Conditional removal of Rb in developing nervous system and lens with rescue of erythropoietic defect. (A) Schematic representation of Rb conditional knockout allele. Cre-mediated recombination removes exon 3 of Rb in tissues expressing Cre from regulatory elements of the rat nestin gene. Abbreviations: P, PstI site, K, KpnI site. (B) Southern blot of genomic DNA from E13.5 whole brain with the genotype Rb1lox/2lox lacking the cre transgene (CON) or bearing the Nes-Cre1 transgene (CRE). Genomic DNA was digested with PstI and the KpnI isoschizomer Acc65I. The bottom 6.5-kb band is the Rb2lox unrecombined allele, while the larger 9-kb band is the recombined Rb1lox allele. (C) Western blot showing tissue-specific loss of Rb conditional mutants carrying the Nes-Cre1 transgene. Tissue is from E13.5 embryos except for skeletal muscle, which was from E18.5 embryos. CON1 refers to control embryos with two copies of the Rb gene product (genotype Rb2lox/+), while CON2 refers to embryos with one copy of the Rb gene product (genotype Rb1lox/2lox). CRE refers to conditional mutants (genotype Rb1lox/2lox) carrying the Nes-Cre1 transgene. Torso is the remainder of embryo lacking the head, liver, and heart. (D) Hematoxylin-eosin-stained sagittal section show normal liver hematopoiesis in conditional-mutant animals, while Rb-/- livers show decreased cellularity and pycnotic nuclei. (E) Peripheral blood smear from E13.5 control, conditional-mutant, or Rb-null embryos. Note the normal ratio of enucleated definitive erythrocytes (open arrows) to nucleated erythrocytes (solid arrows) in the conditional-mutant smear, while Rb -/- smears have very few enucleated erythrocytes. See text for quantitation.
|
Rescue of midgestation apoptosis but not S-phase entry in CNS. We first determined the phenotype of conditional-mutant animals at E13.5, which is the time point that Rb-null embryos normally exhibit high levels of CNS apoptosis. Strikingly, levels of apoptosis in the conditional-mutant embryos were similar to those in controls and dramatically lower than in the Rb-/- CNS (Fig. 3 and 4). The data shown are for the hindbrain, where apoptosis in Rb-null embryos is particularly high; however, equivalent suppression of apoptosis was observed throughout the conditional-mutant brain (data not shown). These data suggest that the death of Rb-/- neurons may be dependent on a hypoxic state induced by defective erythropoiesis. In contrast to the dramatic suppression of CNS apoptosis, the levels of ectopic S-phase determined by BrdU incorporation away from the ventricular zone were similar in conditional mutants compared to Rb-null embryos (Fig. 3 and 4).
![]() View larger version (102K): [in a new window] |
FIG. 3. Apoptosis and S-phase entry in midsagittal sections of hindbrain and fourth ventricle from control, conditional Rb mutant, and Rb-null E13.5 embryos. Hematoxylin and eosin stain (H+E) (A to C) and TUNEL staining (D to F) show apoptotic cells at a magnification of x40. Rb-null (C and F) hindbrain has numerous darkly staining apoptotic bodies, while apoptosis in conditional-mutant (B and E) hindbrain is similar to that observed in controls (A and D). (G to I) BrdU analysis of S-phase entry at a magnification of x40. In controls (G), BrdU-positive cells are restricted to the ventricular zone, while in conditional-mutant (H) or Rb-null (I) sections, extensive ectopic BrdU-positive cells are seen in the intermediate zone.
|
![]() View larger version (34K): [in a new window] |
FIG. 4. Quantitation of apoptosis and S-phase entry in Rb mutant and conditional-mutant embryos. (A) Conditional mutation of Rb leads to apoptosis in the PNS and lens but not in the CNS. Apoptotic cells were quantified as the number of TUNEL-positive nuclei per area of tissue measured in the hindbrain adjacent to the fourth ventricle, DRG, and ocular lens. Apoptosis is expressed relative to the amount seen in Rb-null embryos, which was set to 1.0. Standard deviation is indicated by error bars. (B) Extent of inappropriate S-phase entry is similar between Rb-null embryos and conditional mutants in the lens, CNS, and PNS. For the CNS, ectopic S-phase was quantified as BrdU-positive cells outside of the ventricular zone and quantified per area of tissue measured. For the PNS, overall S-phase in the DRG was quantified per area of tissue measured. For the lens, BrdU-positive cells in the lens fiber compartment were quantified per area of tissue measured. S-phase entry is expressed relative to the amount seen in Rb-null embryos, which was set to 1.0. Standard deviation is indicated by error bars. All data are from 5 to 10 groups of embryos of a given genotype.
|
![]() View larger version (105K): [in a new window] |
FIG. 5. Apoptosis and S-phase entry in sections of DRG from control, conditional Rb mutant, and Rb-null E13.5 embryos. (A to C) TUNEL staining of E13.5 DRG at a magnification of 40x. Note the darkly staining apoptotic cells seen at increased levels in the conditional-mutant (B) and Rb-null (C) sections. (D to F) BrdU staining of E13.5 DRG at a magnification of 40x shows extensive S-phase activity in both conditional-mutant (E) and Rb-null (F) ganglia.
|
![]() View larger version (105K): [in a new window] |
FIG. 6. Apoptosis and S-phase entry in transverse sections of ocular lens from control, conditional Rb mutant, and Rb-null E13.5 embryos. TUNEL staining for apoptosis at a magnification of x40 (A to C) or x100 (D to F) demonstrates numerous darkly stained apoptotic nuclei (arrows) in both conditional-mutant (B and E), and Rb-null lens (C and F) sections, but not in controls (A). BrdU staining at a magnification of x40 (G to I) demonstrates ectopic S-phase entry in the lens fiber cell compartment in lenses from both conditional mutants (H) and Rb-null (I) embryos, whereas BrdU-positive cells are restricted from this compartment in control sections (G).
|
![]() View larger version (73K): [in a new window] |
FIG. 7. Phenotype of conditional-mutant embryos at E18.5. (A) Picture of E18.5 control (CON) and conditional-mutant (CRE) animals. Note the hunched appearance of the conditional-mutant embryo. (B) Conditional-mutant brains are visibly larger than those of littermate controls. (C) Measurement of brain weights indicates that conditional-mutant brains weigh 27% more than littermate controls (t test; P = 0.001). (D) BrdU analysis of ocular lens demonstrates continued ectopic S-phase entry in the conditional-mutant (CRE). (E) TUNEL analysis of lens shows high levels of apoptosis (arrows) in conditional-mutant lens (CRE). (F) Hematoxylin-eosin (H+E)-stained sections of axial skeletal muscle from E18.5 control (CON) and conditional-mutant (CRE) animals demonstrating defective muscle differentiation in conditional mutants. Note the enlarged atypical nuclei (arrows) and abnormal rows of adjacent nuclei apparent in the conditional-mutant sections. The inset shows BrdU analysis demonstrating active DNA-synthesis in abnormally large nuclei in conditional mutant (arrowheads).
|
|
|
|---|
We have previously reported that in E13.5 chimeric embryos composed of both wild-type and Rb-null cells, there was suppression of CNS apoptosis (30) without rescue of inappropriate S-phase entry. There were a number of possible explanations for these findings. For example, in such chimeras, absence of Rb in the cells of the developing CNS might directly trigger the apoptotic program (perhaps as a consequence of cell cycle dysfunction), but this program may be repressed by survival signals stemming from wild-type cells. These survival signals could have originated from cells in the CNS itself in the form of secreted or cell-surface factors. Alternatively, such survival signals could derive from wild-type cells outside of the CNS and be transmitted to the CNS from a distance via the blood. The data from chimeras could also be explained by the existence of proapoptotic factors produced by Rb-/- cells. In this scenario, apoptosis in Rb-/- CNS neurons would be explained by a high-level of such a factor, which could have been produced locally or at a distance. In Rb+/+:Rb-/- chimeras, however, this factor might be diluted below a critical threshold needed for induction of apoptosis.
By using the Nes-Cre1 transgene, we were able to remove Rb throughout the E13.5 brain (Fig. 2c) and observed absence of increased apoptosis in this tissue. The widespread deletion of Rb in the CNS allows us to exclude the possibility that survival signals were sent from wild-type cells in the brain. Also, we can now conclude that CNS apoptosis in Rb-/- embryos is due to the production of a pro-apoptotic signal, and we propose that this signal is hypoxia. Hypoxia has been demonstrated to be an inducer of p53 in neurons and other cell types (3, 16, 28, 50), and there is clear severe anemia and defective development of erythrocytes in Rb-/- embryos. Indeed, the anemia is thought to be responsible for the death of midgestation Rb-/- embryos, and we have demonstrated that conditional Rb mutants with normal erythropoiesis develop until birth. There is also indirect evidence of hypoxia in Rb-/- embryos, with the overexpression of VEGF and LDH-A observed only in germ line Rb mutants but not in the conditional-mutant CNS. We support the hypothesis that the defects in erythropoiesis cause hypoxia, leading to upregulation of VEGF and LDH-A as well as apoptosis. However, it is possible that other unknown cell-extrinsic signals could cause induction of VEGF and LDH-A, and it is still unresolved whether the presence or absence of other signals present in developing Rb-/- blood system might contribute to the death of CNS neurons.
Another unresolved issue is whether Rb-deficient neurons may be sensitized to hypoxia-mediated apoptosis. Rb-/- cells in the CNS show inappropriate S-phase entry that conceivably could make these cells sensitive to hypoxia-induced apoptosis. In cell culture, hypoxia treatment was demonstrated to lead to p53 induction specifically in an S-phase-enriched cell population (19). The mechanism for p53 activation in S-phase was proposed to be via a hypoxia-induced replication arrest and subsequent activation of the ATR kinase upstream of p53 (19). While primary cells in culture have been shown to be resistant to hypoxia-mediated apoptosis, oncogenic transformation of such cells, involving disruption of pRB family function through E1A expression, can confer strong sensitivity to hypoxia-mediated, p53-dependent apoptosis (15). It is possible that loss of cell cycle control in Rb mutants may sensitize these cells to hypoxia-mediated apoptosis. Emerging evidence also suggests that in some systems pRB plays an antiapoptotic role that may be broader than effects of Rb on the cell cycle. For example, exposure of cultured postmitotic neurons to DNA-damaging agents led to rapid phosphorylation of pRB by cyclin-dependent kinases prior to apoptosis (37, 38). Importantly, introduction of a phosphorylation-resistant Rb mutant conferred protection against DNA-damage-induced apoptosis, suggesting that phosphorylation of pRB was important for the progression of apoptosis (31, 37). It has also been proposed that caspase cleavage and subsequent degradation of pRB early in apoptosis is an important event in the execution of apoptosis (8, 23, 42). In cultured neurons and MEFs, introduction of a cleavage-resistant pRB mutant also conferred strong protection against apoptosis (6, 42). pRB-mediated suppression of apoptotic factors may be lost with pRB cleavage or when Rb is constitutively absent through germ line mutation. The proapoptotic signals repressed by pRB are not known; however, in theory such signals could be enhanced in Rb-/- embryos and sensitize neurons to apoptosis. Similarly, Rb-/- MEFs exhibit sensitization to apoptosis induced by DNA damage or growth factor withdrawal (1).
The phenotype of Rb mutant embryos has been used in extensive genetic analyses that have helped define the genetic pathways converging on apoptosis upon Rb loss. In the CNS and lens, E2f1, E2f3, p53, and Apaf1 have all been shown to be required for apoptosis (17, 33, 34, 44, 54). The data presented here may necessitate reinterpretation of these results. For example, given the rescue of both the inappropriate S-phase and apoptosis in the CNS when both E2f1 and Rb were mutated together, it was concluded that inappropriate S-phase through deregulation of E2f activity led to p53 activation (44). Links between deregulated E2F and p53-dependent apoptosis have been found in both cell culture systems and transgenic animals. For example, choroid plexus expression of a fragment of simian virus 40 large T that targets Rb family members but not p53 leads to proliferation and p53-dependent apoptosis, which were both suppressed on an E2f1-deficient background (36). In cell culture, overexpression of E2f1 leads to upregulation of Arf- and p53-dependent apoptosis (5, 24, 40, 49). We subsequently searched for E2F targets that may directly mediate p53 activation in Rb-null embryos and found that the E2F target ARF was not required for p53-dependent apoptosis in the CNS (45). In the CNS, it now appears that the rescue of apoptosis observed with Rb/E2f1 compound mutation may be explained by indirect effects on erythropoiesis. Compound mutation of Rb and E2f1 led to a partial rescue of erythropoiesis at E13.5 (44). However, in contrast to the conditional mutants described here, by E17.0 compound Rb/E2f1 animals appeared anemic and died, indicating that rescue of erythropoiesis was incomplete. We propose that the partial rescue of erythropoiesis in Rb/E2f1 mutants may have been sufficient to reduce the hypoxic stress needed for apoptosis in Rb-/- neurons.
Interestingly, the complete rescue of CNS apoptosis by Rb/E2f1 compound mutation was accompanied by only partial rescue of apoptosis in the PNS (44). Similarly, it was striking that even though apoptosis in the CNS occurred at normal levels in Rb conditional mutants, there was a clear increase in apoptosis in the conditional-mutant PNS. The pathway leading to apoptosis in the Rb-/- PNS is largely undefined. It is known that levels of apoptosis are roughly correlated with levels of inappropriate S-phase entry, that p53 is dispensable for this death, and that caspase3 is required in this system (33, 41). Our present study further confirms that the pathways to apoptosis in the Rb-/- CNS and PNS are functionally distinct. Levels of apoptosis were similar to those in germ line Rb mutants, suggesting that in contrast to CNS neurons, conditional Rb-deficient PNS neurons were not sensitized to apoptosis. The finding that neurons in the PNS were not sensitized to apoptosis induced by the cell-extrinsic signals in germ line Rb mutants indicates that that the apoptotic machinery may be profoundly different in the developing Rb-/- CNS versus PNS. Interestingly, mutation of caspase 3 did not inhibit the CNS apoptosis in germ line Rb-/- embryos but completely inhibited the PNS apoptosis (41). Differences in the importance and amounts of various apoptotic factors such as caspase 3 across different cell types could very well control the life or death of the cell in response to hypoxia or other apoptotic stresses. Therefore, future work elucidating the apoptotic programs activated in response to Rb loss in the different cell types could help us define the basis for these cell type differences. Note that because the Nes-Cre1 transgenic mouse is not specific to the nervous system, we cannot rule out the possibility that deletion of Rb in an unknown tissue compartment could contribute to PNS apoptosis. It will be important to determine the genetics of this p53-independent apoptosis, which appears to be cell autonomous. Because tumors that have mutated p53 are often resistant to chemotherapy, elucidating mechanisms to induce apoptosis in proliferating cells independent of p53 function may be relevant to chemotherapeutic development.
Our findings in the lens further illustrate that the pathway leading to apoptosis upon Rb loss differs in different cell types. p53-dependent apoptosis in Rb conditional-mutant lens still occurred with rescue of the erythropoietic defect, indicating that the pathway upstream of p53 is different in the Rb-null lens versus CNS. In the Rb-deficient lens, previous findings that E2f1 or E2f3 loss led to a rescue of apoptosis point to a role for E2f1 and E2f3 in p53 activation that is more direct than the pathway leading to p53 in the CNS. The findings here related to the Rb-deficient lens agree with our previous observations that adult chimeras composed of Rb-/- and wild-type cells had high levels of apoptosis in the lenses (48), and we also observed high levels of apoptosis in late-gestation E18.5 conditional-mutant lenses (Fig. 7e). Disruption of Rb family function in the lens by expression of the HPV E7 oncoprotein has also been shown to cause lens cell proliferation and apoptosis (35). Apoptosis in this setting was also suppressed by removal of p53 function through E6 expression.
Hypoxia in tumors that have mutated the Rb pathway may indeed be a source of selective pressure for loss of p53 as a means to evade apoptosis. Importantly, hypoxia treatment of oncogenically transformed MEFs in vitro led to selection for cells with mutated p53 (15). In tumors, apoptosis was seen in regions of hypoxia, while p53-null tumors were resistant, suggesting that tumors select for loss of p53 to become resistant to hypoxia-induced apoptosis (15). It may be interesting to search for genetic links between hypoxia and p53-dependent apoptosis in embryos lacking Rb. For example, HIF1
has been implicated in p53 signaling downstream of hypoxia (2, 7), and it would be interesting to know if the pathway to apoptosis in the Rb-deficient CNS is HIF1
dependent. It will also be important to determine if kinases upstream of p53 activation are involved in signaling to p53 in this system. Dissecting the pathways leading to CNS apoptosis in Rb-/- mouse embryos may help to elucidate the pathways that connect hypoxia to p53 activation and selection for p53 mutation in human tumors.
|
|
|---|
. Nature 392:405-408.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»